

**Remarks**

By this Amendment the specification has been amended to reflect prior related applications, to set forth the appropriate sequence identifiers for the sequences listed in Fig. 1, and to add an abstract on a separate page. Additionally, the sequence listing has been replaced with a new sequence listing including a reference to the parent PCT application.

The present application is being filed with a reduced filing fee under 37 CFR 1.492(a)(4), because the international preliminary examination fee was paid to the United States Patent and Trademark Office, and the International Preliminary Examination Report (IPER) stated that the criteria of novelty, inventive step (non-obviousness), and industrial applicability, as defined in PCT Article 33(1)-(4), have been satisfied for all the claims presented in the application entering the national stage.

No new matter has been added by this Amendment.

**Conclusion**

If any minor matters remain to be resolved before examination of this application, please call the undersigned at the telephone number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Anne Carlson, Ph.D.

Registration No. 47,472

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446